University of Kansas Cancer Center Paul Calabresi K12 Career Development Award for Clinical Oncology

摘要 我们建议开发堪萨斯大学癌症中心（KUCC）Paul Calabresi K12职业生涯 临床肿瘤学发展奖（“KUCC K12计划”），其主要目标是培训和发展 通过提供教学课程、研究和职业指导，帮助独立的癌症研究人员。的 KUCC K12计划的主题是临床和转化癌症研究，特别关注 临床试验，利用KUCC的独特优势。KUCC是一个理想的机构，并提供了一个 优秀的环境，培养临床和转化研究人员，因为它在癌症的优势 治疗学、诊断学和医疗器械开发;一个强大的癌症实验治疗学 计划; KUCC共享资源，促进临床试验和相关翻译的进行 以患者为中心的研究。由于没有直接竞争的培训计划，KUCC K12 该计划将是该机构和该地区初级教师的旗舰癌症特定培训计划。 地区KUCC K12计划将通过提供针对癌症的培训来填补KUCC目前未满足的需求 该计划，也有助于填补目前的地理空白，从相对缺乏K12计划在该地区。的 该计划有22名初级导师和24名二级导师-在临床试验方面具有广泛的专业知识， 翻译研究、教学和指导。该计划由罗纳德陈，医学博士，公共卫生硕士， 杰出的临床医生，临床研究员和临床试验员，具有丰富的经验， 教育/指导和培训计划的设计和管理。副项目总监（Scott博士 威尔）和助理PD（博士丽莎哈兰威廉姆斯）带来了翻译研究的互补专业知识， 基础研究、教育项目开发和领导。内部咨询委员会和 外部咨询委员会成员在开发方面提供了大量额外的经验和专业知识， 管理和评估培训计划，包括K12计划。我们将最终确定课程 在第一年培养和招募高质量的学者，并在第二年开始培训学者。我们 建议在第二年招收一名新学者，之后每年招收两名新学者， 将是2-3年。KUCC K12计划的独特之处包括团队科学培训， 技能发展（科学交流和与非专业/社区受众的交流），以及 关于以患者为导向的研究的教学和体验培训，包括将每位学者与训练有素的 病人辩护律师每位学者还将接受指导，以开发临床试验，并将举办K to R研讨会。 指导每位学者撰写一份高质量的独立研究提案。有 以资助第三年的学者培训和额外资助的形式提供了巨大的机构支持 15,000元/年的计划。每位学者每年最多可获得20万美元的补充工资支持， 由该机构提供，以建立学者和他们的临床导向的同事之间的平等。

ABSTRACT We propose to develop The University of Kansas Cancer Center (KUCC) Paul Calabresi K12 Career Development Award for Clinical Oncology (“KUCC K12 Program”), whose primary goal is to train and develop independent cancer researchers by providing didactic coursework, and research and career mentorship. The theme of the KUCC K12 Program is in clinical and translational cancer research, with a particular focus on clinical trials, which leverages the unique strengths of KUCC. KUCC is an ideal institution and provides an outstanding environment to train clinical and translational researchers because of its strengths in cancer therapeutics, diagnostics, and medical device development; a robust cancer experimental therapeutics program; KUCC Shared Resources that facilitate conduct of clinical trials and associated translational components; and patient-centered research. With no directly competing training program, the KUCC K12 Program will be the flagship cancer-specific training program for junior faculty at the institution and in the region. The KUCC K12 Program will fill a current unmet need at KUCC by providing a cancer-specific training program, and also help fill a current geographic void from a relative lack of K12 Programs in the region. The Program has 22 primary mentors and 24 secondary mentors – with extensive expertise in clinical trials, translational research, teaching and mentorship. The Program is led by Ronald Chen, MD, MPH, a distinguished clinician, clinical researcher and clinical trialist, who has extensive experience with education/mentorship and training program design and administration. Associate Program Director (Dr. Scott Weir) and Assistant PD (Dr. Lisa Harlan-Williams) bring complementary expertise in translational research, basic research, and educational program development and leadership. The Internal Advisory Board and External Advisory Board members provide significant additional experience and expertise in the development, administration and evaluation of training programs, including K12 programs. We will finalize curriculum development and recruit high-quality scholars in Year 1 of the award and start training scholars in Year 2. We propose to recruit one new scholar in Year 2 and two new scholars per year after, and each scholar’s training will be 2-3 years. Unique aspects of the KUCC K12 Program include team science training, communication skills development (both scientific communication and communication with a lay/community audience), and didactic and experiential training on patient-oriented research, including pairing each scholar with a trained patient advocate. Each scholar will also be mentored to develop a clinical trial, and a K to R Seminar will mentor each scholar to write a high-quality and submission-ready independent research proposal. There is tremendous institutional support in the forms of funding the third year of scholar training and additional funding of $15,000/year for the Program. Up to $200,000 in supplemental salary support per scholar per year will be provided by the Institution to establish parity between scholars and their clinically-oriented colleagues.